Moderna (NASDAQ:MRNA) PT Lowered to $55.00

Moderna (NASDAQ:MRNA) had its target price cut by analysts at Jefferies Financial Group from $65.00 to $55.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “hold” rating on the stock. Jefferies Financial Group’s target price would indicate a potential downside of 4.28% from the stock’s current price.

A number of other equities analysts also recently issued reports on MRNA. HSBC raised shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price objective on the stock in a report on Wednesday, August 28th. Leerink Partners cut their price target on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a report on Tuesday, September 17th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a report on Friday, September 13th. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and cut their price target for the stock from $85.00 to $80.00 in a report on Wednesday, August 7th. Finally, William Blair reissued a “market perform” rating on shares of Moderna in a report on Thursday, June 27th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $99.81.

Moderna Price Performance

MRNA opened at $57.46 on Tuesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92. The company has a market capitalization of $22.02 billion, a price-to-earnings ratio of -3.67 and a beta of 1.66. The firm’s fifty day moving average price is $71.95 and its two-hundred day moving average price is $105.27. Moderna has a 1 year low of $55.70 and a 1 year high of $170.47.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. The firm had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business’s revenue for the quarter was down 29.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($3.62) EPS. As a group, analysts anticipate that Moderna will post -9.85 earnings per share for the current fiscal year.

Insider Transactions at Moderna

In other news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $117.80, for a total transaction of $1,767,000.00. Following the completion of the transaction, the director now owns 2,239,015 shares of the company’s stock, valued at approximately $263,755,967. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at $682,754. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 33,184 shares of company stock valued at $3,804,931. 15.70% of the stock is owned by corporate insiders.

Institutional Trading of Moderna

Several hedge funds and other institutional investors have recently bought and sold shares of MRNA. V Square Quantitative Management LLC boosted its stake in Moderna by 36.4% in the fourth quarter. V Square Quantitative Management LLC now owns 2,498 shares of the company’s stock worth $248,000 after buying an additional 666 shares in the last quarter. Fisher Asset Management LLC purchased a new stake in Moderna in the fourth quarter worth approximately $206,000. HighPoint Advisor Group LLC purchased a new stake in Moderna in the fourth quarter worth approximately $491,000. Los Angeles Capital Management LLC purchased a new stake in Moderna in the first quarter worth approximately $2,693,000. Finally, GAMMA Investing LLC boosted its stake in Moderna by 37.8% in the first quarter. GAMMA Investing LLC now owns 2,994 shares of the company’s stock worth $319,000 after buying an additional 822 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.